In draft guidance, NICE said evidence collected in the clinical trial and through its own Cancer Drugs Fund (CDF) showed that people with SCCHN live longer when treated with Opdivo than with one of three possible treatments in the comparator arm.
However, the cost-effectiveness agency added that there was uncertainty around these results, as one of the comparator treatments – docetaxel – is used as a standard of treatment for these patients in the NHS…
